Onesource Specialty Pharma Limited — Investor Meet, 19-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

OneSource Specialty Pharma reported strong Q4 FY26 results with revenue up 47% QoQ to INR 428.2 Cr, EBITDA at INR 91.9 Cr, and adjusted PAT of INR 39.0 Cr. Full year revenue was INR 1,421.6 Cr. The company reaffirms its FY28 guidance of US$400 million organic revenue with 40% EBITDA margins.

Growth was driven by initial generic Semaglutide India launches and Canadian approvals for drug-device combinations (DDCs). Capacity expansion, including a second DDC line by Q2 FY27, is on track to meet robust demand. The planned Steriscience merger was deferred to address minority investor concerns. Management is confident in future growth and operational readiness.